PharmaTimes3d
Zydus announces USFDA Orphan Drug Designation for Usnoflast in ALS treatment
Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic lateral sclerosis (ALS). The designation ...
Yahoo Finance5d
FDA approves Zydus’ Phase IIb trial of Usnoflast for ALS treatment
The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb trial of its oral NLRP3 inflammasome inhibitor, Usnoflast, for ...
Mena FN4d
Perjeta Pertuzumab Global Market Set For 15.5% Growth, Reaching $1,932.66 Million By 2029
Perjeta Pertuzumab Global market Report 2025 : Market Size, Trends, And Global Forecast 2025-2034 Perjeta Pertuzumab Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025 ...